ARTICLE | Clinical News
Possia regulatory update
September 27, 2010 7:00 AM UTC
CHMP issued a positive opinion recommending approval of an MAA from AstraZeneca for Brilique/Possia ticagrelor to prevent atherothrombotic events in acute coronary syndrome (ACS) patients. The reversi...